Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain

• DOI: 10.2147/jpr.s176475
• Publication Date: 2018-11-29T18:07:07Z
• Authors: Jingru Zhang; Hong Zhang; Libo Zhao; Jian Gu; Yi Feng; Haiyan An
• Keywords: Flurbiprofen; Active metabolite; NONMEM

Flurbiprofen axetil, a lipid-microsphere-carrier targeting preparation, is non-steroidal anti-inflammatory drug indicated for the treatment of postoperative pain.The aim study was to develop population pharmacokinetic (PPK) model flurbiprofen, active metabolite flurbiprofen and optimize axetil in Chinese patients.A total 144 therapeutic drug-monitoring samples from 72 patients were included this study. The pharmacologically used as analytical target determined 5-45 minutes after intravenous administration. PPK developed using Phoenix NLME 1.3 with nonlinear mixed-effect model. Bootstrap visual predictive checks simultaneously validate final Potential covariates age, sex, body weight, height, body-mass index tested PK parameters.The explained by one-compartment first-order elimination, which hypothetical-effect compartment linked compartment. Population mean values parameters estimated θKe =0.0015/h, θVd =7.91 L, θCL =1.55 L/h. Analysis showed that height weight influenced Ke flurbiprofen. proved be robust.The demonstrated appropriate effective, can assess pain.